Drugs / Vinblastin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03580408 | Aug 2018 → Feb 2021 | classic Hodgkin lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02066220 | Jun 2014 → Dec 2026 expected | brain cancer | University Medical Center Hamburg-Eppendorf | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vinblastin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02066220 ↗ |
| Route | Intravenous | “Vinblastin(6 mg/m2 (IV)” NCT03580408 ↗ |